Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about FBLG, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| SoC + High dose CYWC628 | Diabetic Foot Ulcer (DFU) | Phase 1/2 · NCT07096934 | Recruiting |
| Tolerogenic Fibroblasts | Multiple Sclerosis, Relapsing-Remitting | Early Phase 1 · NCT05080270 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
FBLG holds $3.5M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.8M/quarter from operations, an estimated runway of 2.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 45 · Elevated
These factors raise substantial doubt about our ability to continue as a going concern for one year from the issuance of the financial statements included in this Quarterly Report.10-Q, Jul 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when FBLG files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for FBLG and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →